The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback